Complex　signatures　expressed　at　the　genetic,　transcriptional,　and　epigenetic　levels　influence　tumorigenesis　and　evolution　in　breast　cancer.　A　growing　body　of　evidence　supports　the　close　association　of　RNA　modification　with　the　epigenetic　regulation　of　the　immune　response.　However,　the　mechanism　of　RNA　modification　“writers”　in　the　immunity　of　breast　cancer　remains　indeterminacy.　We　analyzed　genomic　alterations　in　8236　breast　cancer　samples　from　the　cBio　portal　database.　Correlations　between　RNA　“writers”　and　the　expression　of　immunomodulators,　including　immunosuppressants,　immunostimulants,　and　MHC　molecules,　were　calculated　using　the　TIMER　and　TISIDB　databases.　Our　analysis　confirmed　that　abnormalities　in　four　classes　of　RNA　“writers”　were　significantly　correlated　with　poor　prognosis　in　breast　cancer.　In　addition,　abnormal　expression　of　TRMT61B,　a　tumor-associated　RNA　“writer”,　may　be　associated　with　patients　prognosis,　immune　infiltration　levels,　and　expression　of　immunomodulators　in　breast　cancer　patients.　Our　results　suggest　that　TRMT61B　may　serve　as　a　biological　marker　of　breast　cancer　prognosis　and　a　potential　drug　target,　providing　a　novel　idea　for　the　future　therapy　of　breast　cancer.　©　2023,　The　Author(s),　under　exclusive　license　to　Springer　Nature　Switzerland　AG.